• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Neurological Involvement in Primary Systemic Vasculitis
Conclusion Neurological involvement is a common complication of PSV (Table 1), and neurologists play an important role in the identification and diagnosis of PSV patients with otherwise unexplained neurological symptoms as their chief complaint. This article summarizes the neurological manifestations of PSV and hopes to improve neuroscientists' understanding of this broad range of diseases. TABLE 1 Table 1. Common CNS and PNS involvements of primary systemic vasculitis. Author Contributions SZ conceived the article and wrote the manuscript. DY and GT reviewed and edited the manuscript. All authors ...
Source: Frontiers in Neurology - April 25, 2019 Category: Neurology Source Type: research

Incidence, risk factors, and outcomes of stroke post‐transplantation in patients receiving a steroid sparing immunosuppression protocol
This study has identified subgroups of patients who are at increased risk of CVA post‐transplant in patients otherwise receiving a steroid sparing immunosuppression protocol.
Source: Clinical Transplantation - November 19, 2014 Category: Transplant Surgery Authors: Michelle Willicombe, Nicola Kumar, Dawn Goodall, Candice Clarke, Adam G. McLean, Albert Power, David Taube Tags: Original Article Source Type: research

Incidence, risk factors and outcomes of stroke post‐transplantation in patients receiving a steroid sparing immunosuppression protocol
This article is protected by copyright. All rights reserved.
Source: Clinical Transplantation - September 1, 2014 Category: Transplant Surgery Authors: Michelle Willicombe, Nicola Kumar, Dawn Goodall, Candice Clarke, Adam G McLean, Albert Power, David Taube Tags: Original Article Source Type: research